Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
CHLOROMYXIN vs NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
CHLOROMYXIN is not a recognized drug. No data available.
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic